Nanjing Hicin Pharmaceutical Co Ltd

Nanjing Hicin Pharmaceutical Co Ltd has a total equity of 1,053,270,440 CNY and a total debt of 288,344,090 CNY, resulting in a debt-to-equity ratio of 0.27, which is relatively low compared to the industry median. The company's liquidity is assessed as medium, with a current ratio of 1.04, indicating a modest ability to meet short-term obligations. Free cash flow stands at 22,213,070 CNY, while operating cash flow is 78,089,130 CNY, suggesting a moderate cash generation capacity. Profitability metrics show a return on equity (ROE) of 3.99% and a return on assets (ROA) of 2.75%. These figures are below the industry median for ROE and ROA, indicating that the company is underperforming in terms of capital efficiency and asset utilization. The net income of 42,058,390 CNY is also lower than the industry median, reflecting weaker profitability relative to peers. The company's revenue is primarily concentrated in its domestic market, with no significant international operations disclosed. There are no segment disclosures provided in the available data, so it is unclear whether the company operates multiple product lines or therapeutic areas. The lack of geographic diversification and segment detail limits the ability to assess exposure to regional or product-specific risks. Looking ahead, the company's revenue is expected to grow, as the latest actual revenue of 704,087,740 CNY exceeds the reported revenue of 671,048,950 CNY. However, the growth trajectory is not yet clear, and the company's capital expenditures of -62,639,930 CNY suggest a reduction in investment in new projects or facilities. This could indicate a strategic shift or a response to market conditions. The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests potential liquidity constraints. However, the absence of significant dilution risk implies that the company is not likely to issue additional shares in the near term, which is a positive sign for existing shareholders. Recent events include the latest actual revenue report, which shows a revenue of 704,087,740 CNY. No other recent filings or transcripts are available in the provided data, so the company's strategic direction and operational performance remain partially opaque. Investors should monitor future earnings reports and capital allocation decisions for further insight.